Table 1. Association of APOBEC3B copy number status with clinicopathological variables in 1,756 primary breast cancers.
| Variables | Deleted | Balanced | Amplified | P-value | |||
|---|---|---|---|---|---|---|---|
| Total number | 187 | 1260 | 309 | ||||
| Age (in years) | 0.54 | ||||||
| ≤ 40 | 23 | (12.3%) | 160 | (12.7%) | 48 | (15.5%) | |
| 41–55 | 82 | (43.9%) | 498 | (39.5%) | 116 | (37.5%) | |
| 56–70 | 62 | (33.2%) | 412 | (32.7%) | 99 | (32.0%) | |
| >70 | 20 | (10.7%) | 190 | (15.1%) | 46 | (14.9%) | |
| Menopausal status | 0.31 | ||||||
| Premenopausal | 89 | (47.6%) | 554 | (44.0%) | 149 | (48.2%) | |
| Postmenopausal | 98 | (52.4%) | 706 | (56.0%) | 160 | (51.8%) | |
| Tumor size | 1.00 | ||||||
| pT1 | 71 | (38.0%) | 469 | (37.2%) | 115 | (37.2%) | |
| pT2 + Unknown | 96 | (51.3%) | 661 | (52.5%) | 163 | (52.8%) | |
| pT3 + pT4 | 20 | (10.7%) | 130 | (10.3%) | 31 | (10.0%) | |
| Nodal status | 0.041 | ||||||
| N0 | 117 | (63.6%) | 793 | (63.5%) | 173 | (56.5%) | |
| N1-3 | 23 | (12.5%) | 212 | (17.0%) | 67 | (21.9%) | |
| N>3 | 44 | (23.9%) | 244 | (19.5%) | 66 | (21.6%) | |
| Tumor grade | 0.052 | ||||||
| Good/Moderate | 34 | (23.8%) | 193 | (21.9%) | 66 | (29.6%) | |
| Poor | 109 | (76.2%) | 689 | (78.1%) | 157 | (70.4%) | |
| Tumor histology | 0.29 | ||||||
| IDC | 129 | (83.2%) | 833 | (80.6%) | 196 | (78.4%) | |
| ILC | 10 | (6.5%) | 119 | (11.5%) | 30 | (12.0%) | |
| Other | 16 | (10.3%) | 82 | (7.9%) | 24 | (9.6%) | |
| ER status | 0.24 | ||||||
| Positive | 130 | (70.3%) | 951 | (75.8%) | 226 | (73.9%) | |
| Negative | 55 | (29.7%) | 303 | (24.2%) | 80 | (26.1%) | |
| PR status | 0.99 | ||||||
| Positive | 114 | (65.5%) | 779 | (65.8%) | 187 | (65.6%) | |
| Negative | 60 | (34.5%) | 404 | (34.2%) | 98 | (34.4%) | |
| HER2 status | 0.59 | ||||||
| Positive | 18 | (12.6%) | 150 | (15.7%) | 39 | (16.2%) | |
| Negative | 125 | (87.4%) | 807 | (84.3%) | 201 | (83.8%) | |
| Adjuvant systemic therapy | 0.17 | ||||||
| None | 133 | (73.5%) | 856 | (69.9%) | 191 | (63.0%) | |
| Chemotherapy | 26 | (14.4%) | 219 | (17.9%) | 63 | (20.8%) | |
| Hormonal therapy | 22 | (12.2%) | 146 | (11.9%) | 47 | (15.5%) | |
| Both | 0 | (0%) | 4 | (0.3%) | 2 | (0.7%) | |
Note: For nodal status, tumor grade, tumor histology, ER, PR and HER2 status and adjuvant systemic therapy the number of patients do not add up to 1,756 because there were missing values for these variables. In addition, for the adjuvant systemic treatment variable: some patients were not eligible for adjuvant treatment because they were had distant metastasis at the time of primary tumor diagnosis.